Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

INTERACT: a randomized phase 2 study of the DAAO inhibitor luvadaxistat in adults with schizophrenia
Venkatesha Murthy, Elizabeth Hanson, Nicholas DeMartinis, et al.
Schizophrenia Research (2024) Vol. 270, pp. 249-257
Open Access | Times Cited: 11

Showing 11 citing articles:

Therapeutic Potential of DAAO Inhibitors for Cognitive Impairment Associated with Schizophrenia: Learnings from Luvadaxistat
Ryan T. Terry-Lorenzo, Ruicheng Fan, Ni A. Khin, et al.
The International Journal of Neuropsychopharmacology (2025)
Open Access | Times Cited: 1
Negative Symptoms in Schizophrenia: An Update on Research Assessment and the Current and Upcoming Treatment Landscape
Preetika Govil, Joshua T. Kantrowitz
CNS Drugs (2025)
Closed Access
Finding the Right Dose: NMDA Receptor–Modulating Treatments for Cognitive and Plasticity Deficits in Schizophrenia and the Role of Pharmacodynamic Target Engagement
Pejman Sehatpour, Joshua T. Kantrowitz
Biological Psychiatry (2024) Vol. 97, Iss. 2, pp. 128-138
Closed Access | Times Cited: 4
Interpretable machine learning to evaluate relationships between DAO/DAOA (pLG72) protein data and features in clinical assessments, functional outcome, and cognitive function in schizophrenia patients
Chieh‐Hsin Lin, Eugene Lin, Hsien‐Yuan Lane
Schizophrenia (2025) Vol. 11, Iss. 1
Open Access
Treatment of Cognitive Impairment Associated with Schizophrenia Spectrum Disorders: New Evidence, Challenges, and Future Perspectives
Irene Calzavara‐Pinton, Gabriele Nibbio, Sergio Barlati, et al.
Brain Sciences (2024) Vol. 14, Iss. 8, pp. 791-791
Open Access | Times Cited: 2
The Less Things Change, the More They Remain the Same: Impaired Neural Plasticity as a Critical Target for Drug Development in Neuropsychiatry
Joshua T. Kantrowitz, Daniel C. Javitt
Advances in neurobiology (2024), pp. 801-828
Closed Access | Times Cited: 1
Pharmacologie et mode d’action des antipsychotiques
N. Franck, F. Fromager, F. Thibaut
Encyclopédie médico-chirurgicale. Psychiatrie (2015) Vol. 31, Iss. 1, pp. 1-17
Closed Access | Times Cited: 6
Use of video-recordings of site-based interviews for quality assurance in a study of subjects with schizophrenia and persistent negative symptoms
Steven D. Targum, Tingting Ge, Mahnaz Asgharnejad, et al.
Schizophrenia Research (2024) Vol. 272, pp. 61-68
Open Access
How antipsychotics work in schizophrenia: a primer on mechanisms
Jonathan M. Meyer
CNS Spectrums (2024) Vol. 30, Iss. 1
Open Access
Neural Circuitry-Related Biomarkers for Drug Development in Psychiatry: An Industry Perspective
Patricio O’Donnell, Derek L. Buhl, Jason Johannesen, et al.
Advances in neurobiology (2024), pp. 45-65
Closed Access
Evolution of D-amino acid oxidase inhibitors: From concept to clinic
AK Bajaj, Takashi Tsukamoto
Advances in pharmacology (2024), pp. 301-345
Closed Access
Page 1

Scroll to top